AVBCC Value-Based Voices

The Association for Value-Based Cancer Care’s (AVBCC) podcast series addresses the ever-evolving landscape of value related to cancer care in the United States. Our goal is to foster informed dialogue, promote transparency, and empower all players to navigate the rapidly changing landscape of cancer care with clarity and confidence.

AVBCC Value-Based Voices is a business podcast hosted by Rachael, with 13 episodes on record and a Required Pod Score of 80. PitchCentric scores this show on Booking Probability, Listen Score, and live audience signals refreshed every 24 hours.

Rachael hosts AVBCC Value-Based Voices, a business show with 13 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  Episode #13

  Part D Upheaval: Why the Cancer Community Needs to Pay Attention

  Aug 11, 202647 minS1

  In this episode of Value-Based Voices, host Jayson Slotnik, JD, MPH, Partner at Health Policy Strategies, and AVBCC Board Member, sits down with Joel White, Partner and Head of Health Practice at Monument Advocacy, and a principal architect of Medicare Part D, to discuss one of the most consequential challenges facing cancer care today: the end of the Part D Premium Stabilization Demonstration. Bringing unmatched historical insight, policy fluency, and practical clarity to the conversation, Joel breaks down how we got here, how this decision will affect access to cancer therapies, and the real, actionable solutions that could stabilize the market and protect patients. Tune in to gain an understanding for this moment and the path forward! Resources & Links: Medicare Part D overview: https://www.medicare.gov/drug-coverage-part-d Medicare Extra Help / Low-Income Subsidy: https://www.ssa.gov/medicare/part-d-extra-help Connect with Our Guests: Connect with Joel White: / joel-white-6b8a953/ Connect with Jayson Slotnik: / jayson-slotnik-3932305 Contact Value-Based Voices - Follow AVBCC on LinkedIn - View our podcast lineup - Contact us at info@avbcc.org Thanks for listening!

  ListenShow Notes
• 

  Episode #12

  Can the U.S. Keep Its Edge? FDA Policy, China’s Momentum, and the Future of Innovation

  Aug 4, 202638 minS1

  In this follow up conversation, Jayson Slotnik, JD, MPH , Partner at Health Policy Strategies and AVBCC Board Members, and Steve Usdin , Senior Editor, Washington, BioCentury Publications, take a clear eyed look at the future of the FDA and the forces shaping biopharmaceutical innovation. Building on their earlier discussion of FDA history and political dynamics, Steve offers candid insights into how U.S. policy, global competition - particularly with China - and shifting regulatory priorities are influencing the life sciences ecosystem. He explores: - the implications of NIH funding erosion - restrictions on international collaboration - immigration challenges - the growing tension around drug pricing and intellectual property - practical realities companies and investors must navigate in coming months The episode also examines what the FDA can do to strengthen clinical trial efficiency, restore transparency, and rebuild confidence across industry and patient communities. Thoughtful, timely, and grounded in deep policy expertise, this conversation offers listeners a nuanced understanding of where the FDA is headed, and what that means for the future of oncology innovation. If you missed Part 1 of this conversation, catch it here . Resources & Links: BioCentury Publications Operation Trial Blazer Connect with Our Guests : Connect with Steve Usdin Connect with Jayson Slotnik Contact Value-Based Voices - Follow AVBCC on LinkedIn - View our podcast lineup - Contact us at info@avbcc.org Thanks for listening!

  ListenShow Notes
• 

  Episode #11

  The Future of the FDA: What Comes Next?

  Jul 28, 202626 minS1

  In this first of a 2-part series featuring Steve Usdin , Senior Editor, Washington, BioCentury Publications, host Jayson Slotnik, JD, MPH , Partner at Health Policy Strategies and AVBCC Board Member, leads a spirited conversation around developments at the FDA, the political influence shaping its decisions, and the outlook for the future. Key topics covered include: The state of morale among FDA career staff and the challenges in attracting new talent Eroding confidence levels within the investor community and implications for funding Political and ideological influence on FDA activities The debate over the upcoming FDA commissioner appointment and potential candidates The significance of recent initiatives like Operation Trial Blazer in restoring confidence Opportunities for optimism with FDA’s recent engagement with rare disease advocates and international collaboration efforts Resources & Links: BioCentury Publications Operation Trial Blazer Connect with Our Guests: Connect with Steve Usdin Connect with Jayson Slotnik Contact Value-Based Voices - Follow AVBCC on LinkedIn - View our podcast lineup - Contact us at info@avbcc.org Thanks for listening!

  ListenShow Notes
• 

  Episode #10

  Reflections on the NCCN

  Jun 30, 202624 minS1

  In this episode of Value-Based Voices, we delve into the mission and inner workings of the NCCN, a cornerstone organization shaping cancer treatment standards in the U.S. and beyond. We're joined by Bill McGivney, PhD , Principal, McGivney Global Advisors, and Former CEO, NCCN; and host Nicolas Ferreyros , Managing Director, Policy, Advocacy, and Communications, Community Oncology Alliance. Hear expert insights on how guidelines, payer decisions, and evolving technologies influence patient access and outcomes as well as some of Bill's own thoughts on the NCCN and his time at its helm. Resources & Links: National Comprehensive Cancer Network (NCCN) NCCN Guidelines Community Oncology Alliance Connect with Our Guests: Connect with Bill McGivney Connect with Nicolas Ferreyros Contact Value-Based Voices - Follow AVBCC on LinkedIn - View our podcast lineup - Contact us at info@avbcc.org Thanks for listening!

  ListenShow Notes
• 

  AVBCC Value-Based Voices

  Advancing Cancer Research and Innovation through Collaboration at GCRIS 2026

  Jun 16, 202633 min

  We're taking a deep dive into the upcoming Global Cancer Research and Innovation Symposium (GCRIS) in this latest episode of Value-Based Voices. Join GCRIS Scientific Co-chairs Stan Skrzypczak, MS, MBA , Managing Partner, 5 Prime Life Science Consulting, and Nick Sarlis, MD, PhD, FACP , Chief Medical Officer, Cleara Biotech, as they talk with GCRIS Co-chair Matt Vossler , Managing Director, DSG Global, about the groundbreaking science, innovative drug development, and collaborative ecosystems that are reshaping oncology. Hear about: - the rise of "biotech 2.0" - the complexity of bringing new therapies to market - strategies to accelerate drug development cycles and regulatory pathways - what the future holds for researchers and the investors eager to capitalize on emerging science - why GCRIS and its collaborative, unscripted conversations are needed now more than ever Whether you’re in research, investment, or policy, this episode is essential listening for anyone who wants to stay ahead of the curve in cancer innovation. Request your invitation to attend the GCRIS taking place October 5-6, 2026 in New York City: https://avbcc.org/gcris/ ******************************************** Resources & Links • Swim Across America: https://www.swimacrossamerica.org Contact Value-Based Voices - Follow AVBCC on LinkedIn - View our podcast lineup - Contact us at info@avbcc.org Thanks for listening!

  ListenShow Notes

Recent guests on AVBCC Value-Based Voices. Study who booked and why before you pitch.

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.